A new clinical trial has commenced at the Wesley Hospital, investigating the use of Tranexamic Acid in total knee replacements with the goal of improving recovery times and reducing blood loss during and after the procedure.
Total joint arthroplasty can be associated with major blood loss and require subsequent blood transfusions for postoperative anaemia. It is important to research and understand ways to effectively and safely decrease blood loss and reduce the need for blood transfusions. The result of which would help improve patient outcomes and lower health care costs.
Tranexamic acid (TXA) is a medication used to treat or prevent excessive blood loss from major trauma, surgery, tooth removal, and a myriad of other procedures and applications. In this trial, we are investigating a newly developed dosage algorithm for TXA.
Anaesthetist Dr Sue Clark, the Principal Investigator of the study explains, “We do currently understand that with the use of this drug, patients can experience less pain and less bleeding after a total knee replacement surgery, however, there has been no definitive data that shows the ideal dosage and for how long patients should be receiving this drug to optimise their recovery.”
To deliver conclusive data on the use of Tranexamic Acid throughout a patient’s care is an exercise in collaboration.
“We’ve brought the whole team on this journey.” stated Dr Sue Clark. “From the preadmission nurses, through to the theatre nurses, surgeons, recovery staff, ward nurses, as well as the physiotherapists and allied health professionals. Because of this collaboration, we’ll get an answer that will give our patients the very best outcome from their surgery.”
At the conclusion of this study, this new algorithm will help to define exactly the right way to use Tranexamic Acid to ensure patients undergoing a Total Knee Arthroplasty have the best outcomes. These patients will have less pain, less bleeding, and get back to work and life much faster.